Loading page...
Log inCreate account
Loading page...
This round is closed. Synced from the EU Funding & Tenders Portal on 9 November 2026.
Based on projects the EU funded on the same subject in this programme.
IMPROVE-HPVUnderstanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa.
HORIZON-JU-GH-EDCTP3-2023-02-01-two-stage · 2024 · Official record ↗
PROTECTPReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa (PROTECT)
HORIZON-JU-GH-EDCTP3-2023-01-03 · 2024 · Official record ↗
ACTTIVACA Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage · 2026 · Official record ↗
PregInPoxVacMATERNAL AND INFANT SAFETY AND IMMUNOGENICITY IN A PHASE 3, OPEN-LABEL, RANDOMISED, VACCINE TRIAL OF A TWO-DOSE MPOX VACCINE
HORIZON-JU-GH-EDCTP3-2024-Mpox · 2024 · Official record ↗
MVC-2GOptimising a Deployable High Efficacy Multi-Stage Vaccine for Plasmodium falciparum Malaria: 2nd Generation Malaria Vaccine Consortium
HORIZON-JU-GH-EDCTP3-2024-01-02-two-stage · 2025 · Official record ↗
EAVIEUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB-SAHARAN AFRICA
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage · 2026 · Official record ↗
UTI-DiagDiagnostic and Antibiotic Stewardship for Urinary Tract Infections Using Fit-for-Purpose Diagnostic Tools
HORIZON-JU-GH-EDCTP3-2023-02-02-two-stage · 2025 · Official record ↗
OPT-MVACOptimizing the delivery and uptake of malaria vaccines in countries with areas of highly seasonal transmission in West and Central Africa
HORIZON-JU-GH-EDCTP3-2023-02-01-two-stage · 2025 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
Projects funded under this topic should contribute towards the reduction of the burden of disease in SSA and thus contribute to achieving SDG 3 ‘Ensure healthy lives and promote well-being for all at all ages and SDG 13, ‘Climate Action’ through increased international cooperation among researchers and funders, catalyse research synergies, and leverage resources and investment.
Proposals are expected to include the effective in-kind and/or financial contribution of contributing partners, in order to produce more meaningful and significant effects enhancing the impact of the related research activities.
Applicant consortium
The contributions from contributing partners should correspond to the amounts they have committed in the letter of endorsement requesting to become a contributing partner (Article 9 Council Regulation (EU) 2021/2085[1]). Their contributions can consist of financial contributions and/or in-kind contributions. Applicant contributing partners must submit a first draft of the endorsement letter to the Programme Office before the deadline for submission of the second-stage applications[2]. For details on the process on becoming a Global Health EDCTP3 contributing partner, please consult the Guide for contributing partners.
In case of in-kind contribution (even combined with financial contribution), contributing partners become a part of the applicant consortium and participate in the project, as appropriate i.e. as beneficiaries or affiliated entities in the meaning of Article 8 of the Horizon Europe model grant agreement. Also, Global Health EDCTP3 contributing partners can be a country, an international organisation or any public or private legal entity, other than the Global Health EDCTP3 members or their constituent or affiliated entities (please consult the Guide for contributing partners).
Background
Research shows that 3.6 billion people already live in areas highly susceptible to climate change. Climate change is expected to cause worldwide approximately 250 000 additional deaths per year, from malnutrition, malaria, diarrhea and heat stress between 2030 and 2050[3].
Despite its low contribution to the drivers of climate change, Africa will bear high consequences of the changing climate, indicated by rising climate-related health emergencies accounting for more than half of public health events recorded in the region over the past two decades[4]: Out of the 2100+ public health events recorded in the African region between 2001 and 2021, 56% were climate-related. The region is witnessing an increase in climate-linked emergencies, with 25% more climate-related events recorded between 2011 and 2021 compared with the previous decade. More particularly, water-borne diseases accounted for 40% of the climate-related health emergencies over the past two decades [5]. Vector-borne diseases, notably yellow fever, accounted for 28% of the climate-related health emergencies, while zoonotic diseases, specifically Congo-Crimean haemorrhagic fever, being the third most prevalent [6]. Where appropriate, a “One Health” approach is recommended to address climate-related public health events. The approach is based on the premise that human, animal and ecosystem health is interconnected and requires a coordinated approach to tackle and resolve the challenges.
In addition, vulnerable populations in Africa, particularly the low-income households, women, children, and rural communities, are disproportionately affected by climate change because they face higher exposure to extreme weather, depend heavily on climate-sensitive agriculture productivity, and have limited resources and institutional capacity to adapt, which deepens poverty, food insecurity, health risks, and displacement.
Changing climate conditions (such as temperature, humidity and precipitation levels) have an impact on the geographical and seasonal distribution of infectious diseases, with weather affecting the timing and intensity of disease outbreaks. This results in particular disease-carrying vectors becoming of relevance for Europe. In addition to climatic factors, regional disease risks are also affected by factors such as land use, vector control, human behaviour, global trade and travel, and public health capacities[7].
Climate change is also increasing Europe’s risk to water-borne diseases by degrading water quality through flooding, heatwaves, and droughts, thereby heightening risks of gastrointestinal infections and other health issues, especially when sanitation and infrastructure are inadequate [8].
With this, the European Commission’s Strategic Research and Innovation Agenda on Health and Climate Change[9] – launched in mid‑2025 – sets out a comprehensive R&I roadmap with cross‑cutting priorities including climate‑driven health inequalities, inter‑sectoral data systems, climate adaptation in healthcare systems, and the development of transdisciplinary, global knowledge partnerships (HERA, EC DG RTD, SRIA 2025). This prioritisation underscores the alignment between the EC’s SRIA and Global Health EDCTP3 objectives, emphasising the need for integrated, equitable, and internationally cooperative research efforts addressing climate-change driven infectious diseases.
Together, these frameworks and epidemiologic trends demonstrate the urgent need for Global Health EDCTP3 to fund research on climate-sensitive water- and vector-borne diseases – with a potential dual focus on sub‑Saharan Africa (SSA), where the burden is high and rising, and Europe, where endemic risk is rapidly emerging. In this effort, vulnerable populations in SSA should not be left behind.
Investments in surveillance, climate-adaptive early warning systems, diagnostic and genomic capacity, vector control innovations, One Health approaches, and health system resilience are essential. Aligning with Africa CDC/AU and EC SRIA targets, Global Health EDCTP3 can catalyse cross‑continental innovation, strengthen global health security, and mitigate an escalating threat to relevant vulnerable populations.
Expected Outcomes
Proposals submitted under this topic should aim to deliver results that are contributing to improved health outcomes related to climate sensitive vector- and water-borne pathogens in the scope of the Global Health EDCTP3 SRIA[10] in SSA.
In addition, proposals are also expected to lead to:
Proposals under this topic should include:
A/ Minimum one of the following:
B/ In addition, proposals should address ALL of the following:
C/ In addition, the proposals should address at least two of the following:
Climate-sensitive infectious diseases are defined in scope of this call as diseases whose incidence, prevalence, or intensity is negatively impacted by climate change and includes the vector- and water-borne pathogens in the scope of the Global Health EDCTP3 SRIA.
Proposals are encouraged to integrate climate-epidemiological models integrating humans, animals and ecosystems under different climate scenarios and to indicate how it will contribute to improving the preparedness of health security related to climate sensitive pathogens in (Southern) EU.
Preclinical studies are considered out of scope of the topic.
However, preparatory activities conducted during the preclinical phase can be considered in scope if they enable the conduct of the clinical study/ies in scope (these activities include but are not limited to protocol writing, development/evaluation of laboratory tests, CMC related activities, etc.).
For all Global Collaboration Actions such as this topic, proposals submitted are expected to leverage financial and/or in-kind contributions from contributing partners. Proposals should define the activities of their project in its entirety, including details of the component(s) for which Global Health EDCTP3 funding is requested and the component(s) that are to be financed by contributing partners. Each contribution should be well described and budgeted in each proposal, so that the activities and related costs that are covered by the in-kind or financial contribution(s) are clearly identified.
Applicants are to provide data on the impact of climate change on the chosen disease, and how the proposed study would ameliorate the negative impact.
Applicants will be expected to include a fair representation of health and climate experts and One Health experts in their consortium composition, as relevant, and provide methodologies for translating research findings into public health/climate practice and policy guidelines and are encouraged to follow guidance provided in the EDCTP Knowledge Hub Research into Policy Toolkit. Multidisciplinary approaches with the integration of adjacent sectors are encouraged (i.e. nutrition, IPC/WASH, etc.).
When relevant, proposals should clearly describe the desired target product profile. Applicants need to concisely describe any prior relevant research findings and explain how the proposal builds on available data (including data generated in scope of earlier EDCTP programmes if available). Full details of the development milestones, including specific go/no-go criteria for the implementation of the proposed clinical trial(s) must be included, as well as specific plans for the subsequent regulatory approval process, which should aim at obtaining relevant market authorisation and an access strategy that will allow patients in low-resource settings to access the final product.
The applicants are encouraged to consider the latest innovations and advances in the clinical trial design and research methods in order to evaluate promising interventions allowing shorter development timings. Applicants are also encouraged to follow the WHO Guidance for best practices for clinical trials.
Proposals should engage communities and relevant stakeholders, most notably (local) key opinion leaders, researchers, health care professionals, policy makers, public health authorities and end-users.
Applicants are reminded of the expectation that proposals should come from research consortia with a strong representation of institutions and researchers from SSA countries, including involvement of Franco/Lusophone countries, if possible. Collaboration with other international research groups with relevant experience is very much encouraged. Applicants are also reminded of the expectation of reaching out to organisations in countries with relatively lower research capacities.
All projects funded under this topic are strongly encouraged to participate in networking and joint activities, as appropriate. These networking and joint activities could, for example, involve the participation in joint workshops, the exchange of knowledge, and local data collected, the development and adoption of best practices, external conferences joint communication and dissemination activities. Applicants should anticipate budget to cover this collaboration. The details of these joint activities will be defined during the grant agreement preparation phase. Collaboration and coordination with existing adaptive platform trials in Africa and Europe, EDCTP’s Networks of Excellence and other EDCTP funded initiatives is encouraged, where relevant.
[1] Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014
[2] The Global Health EDCTP3 Programme Office will ask the applicant contributing partner to revise the letter in case it significantly departs from the template letter published on the Global Health EDCTP3 website or is missing any compulsory elements. The final decision as to acceptance or rejection of a new contributing partner rests with the Global Health EDCTP3 Governing Board.
[3] WHO | Climate Change
[4] WHO | Africa faces rising climate-linked health emergencies
[5] Idem
[6] idem
[7] Vector-borne diseases | Health effects | European Climate and Health Observatory Climate-ADAPT
[8] Water-borne disease | Health effects | European Climate and Health Observatory Climate-ADAPT
[9] Strategic research and innovation agenda on health and climate change - Publications Office of the EU
[10] Global Health EDCTP3 Strategic Research and Innovation Agenda
1. Admissibility Conditions: Proposal page limit and layout
described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
2. Eligible Countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligible Conditions
The conditions are described in General Annex B except for the specific conditions for the Global Health EDCTP3 JU funding as regards entities eligible for funding and consortium composition, the specific rule for countries where the coordinator may be established and the obligation to designate a scientific project leader as below.
Specific conditions replacing the relevant sections in General Annex B to the Horizon Europe Work Programmes
A. Entities eligible for funding
This section applies to both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA).
To become a beneficiary, legal entities must be eligible for funding. To be eligible for funding, applicants must be established in one of the following countries:
Legal entities which are established in countries not listed above (including in low-and middle-income countries that are not members of the EDCTP Association) will be eligible for funding if provided for in the specific call topic conditions, or if their participation is considered essential for implementing the action by the granting authority.
B. Consortium composition
Unless otherwise provided for in the specific call conditions, for all actions, due to the policy objectives of Global Health EDCTP3, legal entities forming a consortium are eligible to participate in actions under the programme provided that the consortium includes as beneficiaries:
This condition applies to both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA).
For the two CSA (2) topics under call HORIZON-JU-GH-EDCTP3-2026-03 in case the applicant consortia opt for including the EDCTP Association as coordinator, the EDCTP Association must not be counted as one of the three independent legal entities necessary to ensure the eligibility of the consortium composition.
Specific cases:
Affiliated entities — Affiliated entities are eligible for funding under the same conditions as beneficiaries.
Associated partners — Entities not eligible for funding and therefore not able to participate as beneficiaries or affiliated entities (i.e. entities which participate in the action without signing the grant agreement, and without the right to charge costs or claim contributions) are allowed, subject to any conditions regarding associated partners set out in the specific call conditions.
International organisations – International European research organisations are eligible to receive funding. Other international organisations are not eligible to receive funding unless their participation is considered essential for implementing the action by the granting authority. International organisations with headquarters in a Member State or associated country are eligible to receive funding when provided for in the specific call conditions.
Specific rules regarding legal entities that may be the coordinator of an indirect action
In accordance with Article 110(2) of the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014, p. 17–119.]], where entities established in a third country without an agreement to protect the financial interests of the Union participate with funding in an indirect action, the coordinator of the indirect action must be established in a Member State or associated country, or South Africa.
Scientific project leader
If the coordinator is not established in a country in SSA (please see previous paragraph), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described below is mandatory. A work package on ‘scientific project leadership’ must be included in the proposals and budget needs to be provided for this activity. The scientific project leader oversees the project scientific governance and leadership. For this purpose, proposals must include a work package where the details of scientific project leadership are laid down. The scientific project leader should indicatively perform the following tasks:
Annex 1 to the grant agreement and the consortium agreement should address the relationship of the scientific project leader with the coordinator regarding their respective tasks, for example sharing of the information received from or sent to Global Health EDCTP3 on all issues of interest for the proper scientific management of the action.
described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
Specific conditions related to Scores and weighting
Replacing the scores and weighting section in General Annex D to the Horizon Europe Work Programmes as regards second stage of two-stage evaluations, for Research and Innovation Actions (RIA). Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criterion 3 (Quality and Efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.
Proposals that pass the individual threshold and the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.
Nota bene: for the CSAs and the first stage of the two-stage evaluation of RIAs, the scores and weighting as indicated in Annex D of the General Annexes of the Horizon Europe work programme 2023/2025 apply.
In addition to the aspects of award criteria included in General Annex D, the following aspects are taken into consideration during the evaluation of second-stage proposals:
For the ‘impact’ criterion: Production of meaningful and significant effects enhancing the impact of the relevant research activities via the inclusion of effective in-kind and/or financial contribution of contributing partners.
For the ‘quality and efficiency of the implementation’ criterion: Leveraging of financial and/or in-kind contributions from contributing partners that are equal or greater than the requested JU contribution, in order to ensure the necessary resources and effort for the action.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
Implementing the provision on affordable access as defined in Article 114 of the Council Regulation 2021/2085[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014, p. 17.]], grants awarded under this topic will have to include in their Plan for the exploitation and dissemination of results including communication activities to be submitted during the project as a deliverable also the following:
Access plan
Participants must include in their Plan for the exploitation and dissemination of results[[For more information on the Plan for the exploitation and dissemination of results, please consult the General Annexes of Horizon Europe Work Programmes.]] an appropriate and proportionate access plan that demonstrates their strategies to ensure that the products and services that they develop based or partly based on the results of clinical studies undertaken by their project are affordable, available and accessible to the public (market and end-users) at fair and reasonable conditions. This covers registration targets, plans to meet demand, flexible approaches to IP, engagement with regulators and manufacturers where relevant and other strategies that reflect ability to pay and ensures that economic barriers to access are low. In addition, participants should add, if relevant, as part of the plan, an outline on how to achieve the optimal use of an intervention including, for example, how to avoid irrational use, overuse or abuse (e.g. antimicrobials).
The plan is to be submitted with the second-stage proposal. In addition to any updates during the project, a final version of the Plan for the exploitation and dissemination of results including the above access plan, must also be submitted with the final report of the project.
Also in line with Article 114 of the Council Regulation 2021/2085[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014]], participants will be subject to the following additional exploitation obligations:
described in Annex G of the Work Programme General Annexes.
JU right to object to transfer/exclusive licensing
Global Health EDCTP3 may, up to four (4) years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5 of the Model Grant Agreement. In addition, in accordance with Article 24(3) of Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014, p. 17.]] and the Model Grant Agreement, the right to object applies also to participants that have not received funding from the JU.
[1] Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014, p. 17.
Information sharing regarding the proposals and the evaluation results
Applicants should be aware that the following information regarding their proposals may be shared with the members of the JU Committee of the EDCTP Association:
1. Following eligibility check of the applications: aggregated country level data i.e. number of applicants, funding requested, organisation type;
2. For successful proposals, following Global Health EDCTP3 Governing Board decision on the call evaluation results: number; acronym; title; duration; role; country; legal name; PIC; legal type; total cost; requested JU contribution;
3. Regarding project information following Grant Agreement (GA) signature: signature date of the GA; number, acronym, title, and duration of projects; role, country, legal name, PIC, legal type, URL, total cost, requested JU contribution, FC received, FC given, and IKOP of participants;
4. Under specific conditions and following Global Health EDCTP3 Governing Board approval of the request of EDCTP Association, for proposals on the reserve list and unsuccessful proposals: number; acronym; title; duration; role; country; legal name; PIC; legal type; total cost; requested JU contribution.
Access to information and involvement of contributing partners
Evaluation
To promote transparency and accountability, Global Health EDCTP3 may invite any contributing partners providing financial contributions under a certain topic to propose one representative as observer to participate in the evaluation process under confidentiality safeguards. This possibility does not apply to contributing partners that are part of a consortium submitting a proposal under the relevant topic.
Documents and information
By applying under any topic, participants consent that the JU reserves the right to share information and documents relevant to their application and where applicable their grant agreement and its implementation with contributing partners as identified and providing financial contributions under the relevant topic. This information and documentation will only be shared under confidentiality safeguards for policy and monitoring purposes. They include:
Global Health EDCTP3 may consult the relevant contributing partners for the purpose of assessing the project reports and deliverables.
Other requirements
For all projects under this topic, if the coordinator is not from a country in SSA, the designation of a scientific project leader with the roles as described in the introduction is mandatory. A work package on ‘scientific project leadership’ must be included in the proposals and budget needs to be provided for this activity.
Annual Work Programme 2026
Global Health EDCTP3 Calls for proposals
Application and evaluation forms and model grant agreement (MGA):
Application form templates — the application form specific to this call is available in the Submission System
Note: despite blind evaluation being mentioned in the standard application form for stage 1 proposals of the two-stage calls available in the Funding and Tenders Portal (at the stage of adoption of this Work Programme), please note that the calls included in this WP are not part of the ‘blind evaluation pilot’, therefore no anonymisation is required for stage 1 proposals of the two-stage calls.
Standard application form (HE RIA IA Stage 1)
Evaluation form templates — will be used with the necessary adaptations 
Standard evaluation form (HE RIA, IA and CSA Stage 1) 
Guidance
HE Programme Guide
Model Grant Agreements (MGA)
HE MGA
Call-specific instructions
Information on clinical studies (HE)
Additional documents:
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 4. Health
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Programme Guide
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual 
Funding & Tenders Portal Terms and Conditions 
Funding & Tenders Portal Privacy Statement
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-09
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.